AbCellera Biologics Inc. Q1 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) held its First Quarter 2026 Business Update Conference Call on May 11, 2026. The call featured key executive participants, including CEO and President Dr. Carl Hansen, Chief Medical Officer Dr. Sarah Noonberg, and Chief Financial Officer Andrew Booth. Tryn Stimart, the Chief Legal and Compliance Officer, opened the session by welcoming attendees and issuing standard forward-looking statement disclaimers in accordance with the Private Securities Litigation Reform Act of 1995. She highlighted that discussions regarding strategic priorities and financial outlooks are based on current expectations and subject to various risks and uncertainties. Investors were advised to review the Risk Factors section in the company's recent SEC filings, such as Form 10-K and 10-Q, for detailed information on potential variables affecting actual results. The event included participation from major financial analysts representing institutions like Stifel, BMO Capital Markets, Truist Securities, Piper Sandler, TD Cowen, JonesTrading, and Cantor Fitzgerald. This transcript serves as a record of the corporate communication regarding AbCellera's financial performance and operational updates for the first quarter of 2026, providing stakeholders with insights into the company's current standing and future projections.
Wire timeline
AbCellera Biologics Inc. Q1 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) held its First Quarter 2026 Business Update Conference Call on May 11, 2026. The call featured key executive participants, including CEO and President Dr. Carl Hansen, Chief Medical Officer Dr. Sarah Noonberg, and Chief Financial Officer Andrew Booth. Tryn Stimart, the Chief Legal and Compliance Officer, opened the session by welcoming attendees and issuing standard forward-looking statement disclaimers in accordance with the Private Securities Litigation Reform Act of 1995. She highlighted that discussions regarding strategic priorities and financial outlooks are based on current expectations and subject to various risks and uncertainties. Investors were advised to review the Risk Factors section in the company's recent SEC filings, such as Form 10-K and 10-Q, for detailed information on potential variables affecting actual results. The event included participation from major financial analysts representing institutions like Stifel, BMO Capital Markets, Truist Securities, Piper Sandler, TD Cowen, JonesTrading, and Cantor Fitzgerald. This transcript serves as a record of the corporate communication regarding AbCellera's financial performance and operational updates for the first quarter of 2026, providing stakeholders with insights into the company's current standing and future projections.
All Articles on Seeking Alpha